Takeda and Protagonist Therapeutics’ rusfertide has received FDA approval for polycythemia vera, with the drug branded as Mimrylo. The clearance enables the product to enter prescription use for the rare blood disorder, expanding Takeda’s portfolio in hematology. Rusfertide is positioned as a new therapeutic option for polycythemia vera, an illness associated with elevated red blood cell mass and thrombotic risk. The approval follows the typical FDA evaluation pathway for rare-disease therapeutics where meaningful clinical benefit endpoints drive regulatory decisions. The decision also increases competitive intensity in a crowded hematology market where differentiated mechanisms and safety/tolerability profiles determine prescribing behavior.